Cited by 94Treatment of Major DepressionBipolar Disorder and TreatmentPsychological Treatments and Disorders

Lithium in the treatment of major depressive disorder

Bschor, Tom·2014·Drugs

Abstract

Recent high-quality studies have confirmed the central role of lithium in the treatment of bipolar disorder and have established lithium as the drug of first choice for long-term prophylaxis in this condition. However, several indications for its use in unipolar major depression are also based on sound evidence. This includes lithium augmentation as a main strategy for depressed patients not responding to an antidepressant, lithium prophylaxis for recurrent unipolar depression as an alternative to prophylaxis with an antidepressant, and lithium's unique anti-suicidal properties. Lithium monotherapy, on the other hand, is not established for acute treatment of depression. Lithium therapy should be a core competency of every psychiatrist, enabling the safe use of lithium, to the benefit of our patients.

Integrity signals

Registry

Crossref · 10.1007/s40265-014-0220-x

Cites

56 of 56 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Bschor, T.
Affiliations
Schlosspark-Klinik (DE)
Corresponding author
Bschor, Tom
Venue
Drugs
Published
2014-05-14
Volume
74
Issue
8
Pages
855-862
ISSN
  • 0012-6667 (ISSN-L)
  • 1179-1950
OpenAlex
W1994511645
Cited by
94
References
56
Citations by year
2026: 4 · 2025: 5 · 2024: 7 · 2023: 8 · 2022: 10 · 2021: 10 · 2020: 9 · 2019: 5 · 2018: 9 · 2017: 8 · 2016: 4 · 2015: 11 · 2014: 4
FWCI
1.15
Type
journal article
Language
en
Open access
closed
Locations
  • Drugs (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Eli Lilly and Company
  • AstraZeneca
  • H. Lundbeck A/S
Topics
  • Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
  • Social Sciences › Psychology › Clinical Psychology › Psychological Treatments and Disorders
Keywords
lithium, major depressive disorder, bipolar disorder, lithium augmentation, antidepressant-resistant depression, depression prevention, suicide prevention, lithium monotherapy
MeSH terms
Suicide Prevention, Antidepressive Agents, Bipolar Disorder, Major Depressive Disorder, Humans, Lithium Compounds

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review